Pharmaceutical Overview
Lanoxin 0.25 mg is a pharmaceutical-grade digoxin preparation manufactured by GlaxoSmithKline, representing a cardiac glycoside compound extensively investigated in cardiovascular research. This preparation provides researchers with a standardised reference material for studying digitalis glycoside mechanisms and myocardial contractility modulation. The compound serves as a benchmark for investigating cardiac electrophysiology, sodium-potassium ATPase inhibition, and intracellular calcium handling in cardiac muscle preparations.
Research Applications
Research teams at Stroid UK Shop examine Lanoxin formulations to investigate digitalis pharmacology, cardiac ion channel interactions, and myocardial force-frequency relationships. Studies explore the compound’s effects on cardiac output, heart rate variability, and arrhythmogenic potential in various experimental models. Investigations include assessment of therapeutic windows, drug interactions with other cardiovascular agents, and comparative studies with other cardiac glycosides. The preparation enables research into digoxin’s effects on atrial fibrillation models, heart failure pathophysiology, and cardiac remodelling processes. Additional research focuses on digoxin’s non-cardiac effects, including potential neuroprotective properties and anti-inflammatory mechanisms. Contemporary studies examine the compound’s interaction with modern cardiovascular therapies, biomarker correlations, and pharmacogenomic factors affecting digoxin sensitivity. Researchers also investigate selective androgen receptor modulators and research peptides alongside cardiac glycosides in comprehensive cardiovascular research programmes. Some investigations compare digoxin effects with other compounds available in research chemical collections for multi-pathway cardiovascular studies.
Technical Specifications
| Parameter | Specification |
|---|---|
| Active Ingredient | Digoxin |
| Strength | 0.25 mg |
| Manufacturer | GlaxoSmithKline |
| CAS Number | 20830-75-5 |
| Molecular Formula | C₄₁H₆₄O₁₄ |
| Molecular Weight | 780.95 g/mol |
| Storage Requirements | Room temperature, dry conditions |
Research Compliance
This Lanoxin preparation is supplied exclusively for in-vitro research applications and laboratory analysis. The product is not intended for human consumption, clinical use, or any therapeutic applications. Researchers must ensure appropriate institutional approvals, safety protocols, and waste disposal procedures when handling this pharmaceutical reference material. All investigations should comply with relevant research ethics guidelines and institutional review board requirements.
